Financings Roundup: Optimer, Sopherion, Proteon, Pearl
This article was originally published in The Pink Sheet Daily
Recent alternative financings include direct offerings to institutional investors, a private biotech out-licensing its lead compound to a holding company, and the latest equity/option deal for Novartis’ corporate venture with MPM Capital.
You may also be interested in...
Alnylam, Isis keep ownership of joint venture for now, but status change could bring more investors aboard by 2011.
Phase III data show antibiotic non-inferior to Vancocin; additional trial results due mid-2009 with an NDA filing by year’s end.
In mid-September, the MPM Capital/Novartis investment fund closed a $10 million investment in Radius Health -- getting an option on Radius's Phase II osteoporosis candidate and the first evidence that its strategy of melding business development with VC can work. And that's why the outcome will be important to watch. If the Radius deal is followed by others, Big Pharma will try to copy the model. If the deal is seen as preventing Radius from getting a profitable exit for its investors, serving Novartis' needs at their expense, corporate VC will go back to the drawing board.